Tag: LMICs
-
Runcie C.W. Chidebe and the Power of Cancer Support Groups in Nigeria and LMICs
Why Cancer Support Groups Matter in Nigeria and LMICs Runcie C.W. Chidebe, Executive Director of Project PINK BLUE, has long championed patient-centered cancer care in Nigeria and other low- and middle-income countries (LMICs). In discussions that followed a notable publication, Chidebe underscored the transformative role that cancer support groups play in improving outcomes, reducing stigma,…
-
Cancer Support Groups in Nigeria and LMICs: Essential Care
Why cancer support groups are essential to care in Nigeria and LMICs Runcie C.W. Chidebe, Executive Director of Project PINK BLUE, recently highlighted a growing recognition among health advocates: cancer support groups are not a luxury but a cornerstone of comprehensive cancer care in Nigeria and other low- and middle-income countries (LMICs). In settings where…
-
Global Analysis Finds Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
Overview: A Global Portrait of Cancer Care Gaps A sweeping study by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine exposes persistent disparities in the way three of the most common cancers among women—breast, cervical, and ovarian cancer—are diagnosed and treated around the world. The findings highlight how geography, income…
-
Lenacapavir PrEP Price Drop: From $28,000 to $40 Expands Access
What is Lenacapavir and how does it work as PrEP? Lenacapavir is a long-acting HIV prevention drug (PrEP) that is administered as an injection twice a year. In the European Union, it has been approved for preventive use under the brand name Yeytuo, with Gilead as the manufacturer. Early studies have shown near-total protection against…
-
Lenacapavir: HIV prevention price slashed for LMICs
What is Lenacapavir and why does it matter for HIV prevention? Lenacapavir, marketed under the brand name Yeytuo, is a long-acting HIV prevention treatment that is injected twice a year. The EU approval placed it among the few options designed to simplify and strengthen pre- exposure prophylaxis (PrEP) by reducing the burden of daily pills.…
-
Lenacapavir Agreement: A Breakthrough in HIV Prevention
Introduction to Lenacapavir In a groundbreaking development for global health, a new injectable HIV prevention tool, lenacapavir, is set to be available at an astonishingly low price of just US$40 per year in 120 low- and middle-income countries (LMICs). This significant milestone comes as part of a landmark agreement announced on September 24, 2025, involving…
-
Revolutionary HIV Prevention: Lenacapavir Made Affordable
Introduction to Lenacapavir On September 24, 2025, a landmark agreement was reached to bring the groundbreaking HIV prevention tool, injectable lenacapavir, to 120 low- and middle-income countries (LMICs) at an astonishing cost of just $40 per year. This partnership between Dr. Reddy’s Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI marks a…